MedTrace Logo

Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy

NCT00041795 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2005-06-24

No results posted yet for this study

Summary

This study will assess the safety and efficacy of Neotrofin in treating the peripheral neuropathy that results from chemotherapy for cancer.

Conditions

  • Peripheral Nervous System Diseases
  • Chemotherapy-Induced Peripheral Neuropathy

Interventions

DRUG

leteprinim potassium (Neotrofin)

Sponsors & Collaborators

  • NeoTherapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00041795 on ClinicalTrials.gov